GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DanCann Pharma AS (XSAT:DANCAN) » Definitions » LT-Debt-to-Total-Asset

DanCann Pharma AS (XSAT:DANCAN) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is DanCann Pharma AS LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. DanCann Pharma AS's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

DanCann Pharma AS's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).


DanCann Pharma AS LT-Debt-to-Total-Asset Historical Data

The historical data trend for DanCann Pharma AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DanCann Pharma AS LT-Debt-to-Total-Asset Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial - - - - -

DanCann Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DanCann Pharma AS LT-Debt-to-Total-Asset Calculation

DanCann Pharma AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=0/15.062
=0.00

DanCann Pharma AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=0/15.062
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DanCann Pharma AS  (XSAT:DANCAN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


DanCann Pharma AS LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of DanCann Pharma AS's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


DanCann Pharma AS Business Description

Traded in Other Exchanges
N/A
Address
Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.

DanCann Pharma AS Headlines

No Headlines